TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Cyclopharm Limited ( (AU:CYC) ) is now available.
Cyclopharm Limited has released its 2024 Annual Report, highlighting its position as a global leader in functional lung ventilation imaging. The report underscores the company’s commitment to innovation and its strong market presence with Technegas™, which is widely used in 66 countries, reflecting its significant impact on the healthcare industry.
More about Cyclopharm Limited
Cyclopharm Limited is a health technology company specializing in functional lung ventilation imaging. Its proprietary product, Technegas™, is a leader in diagnostic imaging and is available in 66 countries.
YTD Price Performance: -24.05%
Average Trading Volume: 164,691
Technical Sentiment Signal: Buy
Current Market Cap: A$133.4M
For detailed information about CYC stock, go to TipRanks’ Stock Analysis page.